

Supplementary Information:

**Cardiovascular disease progression in female Zucker Diabetic Fatty rats
occurs via unique mechanisms compared to males**

Kelly Lum-Naihe^{#,1,5}, Ryan Toedebusch^{#,1,4,5}, Abuzar Mahmood^{1,4,5}, Jamal Bajwa^{1,5}, Terry Carmack⁵, Senthil A. Kumar¹, Sivakumar Ardhanari¹, Vincent G. DeMarco^{1,5},

Craig A. Emter^{2,4} and Lakshmi Pulakat^{*1,3,4,5}

[#]Co-first authors

Departments of Medicine¹, Biomedical Sciences², Nutrition and Exercise Physiology³, Dalton Cardiovascular Research Center⁴, University of Missouri, and Harry S Truman VA Hospital⁵,
Columbia, MO


***Corresponding Author:**

Dr. Lakshmi Pulakat
Department of Medicine and Department of Nutrition and Exercise Physiology
Dalton Cardiovascular Center
University of Missouri School of Medicine
Columbia, MO 65212
Email:pulakatl@health.missouri.edu

Supplemental Table S1. Comparison of systolic and diastolic function of 3- and 5-month old male and female ZL and ZDF rats.

| | ZL-F | | ZDF-F | | ZL-M | | ZDF-M | | 2x2 RM ANOVA |
|--------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|----------------------------|
| | 3 mos. | 5 mos. | 3 mos. | 5 mos. | 3 mos. | 5 mos. | 3 mos. | 5 mos. | |
| SYSTOLIC FUNCTION | | | | | | | | | |
| HR (beats/min) | 312 ± 10 | 301 ± 10 | 373 ± 11 | 349 ± 9 | 307 ± 9 | 347 ± 11 | 280 ± 10 | 266 ± 4 | INT, ME-sex |
| FS (%) | 57 ± 3 | 58 ± 1 | 53 ± 2 | 65 ± 4 | 45 ± 2 | 52 ± 2 | 50 ± 1 | 51 ± 1 | INT, ME-sex |
| LV SV (µL) | 378 ± 45 | 450 ± 30 | 314 ± 34 | 410 ± 23 | 425 ± 31 | 479 ± 25 | 481 ± 27 | 447 ± 55 | ME-sex |
| LVAWs (mm) | 2.8 ± 0.2 | 3.1 ± 0.2 | 3.1 ± 0.2 | 3.4 ± 0.1 | 3.0 ± 0.1 | 3.4 ± 0.1 | 3.1 ± 0.1 | 3.4 ± 0.1 | |
| LVPWs (mm) | 2.2 ± 0.1 | 2.7 ± 0.2 | 2.5 ± 0.1 | 3.4 ± 0.3 | 2.4 ± 0.1 | 2.7 ± 0.1 | 2.5 ± 0.1 | 3.0 ± 0.1 | ME-diabetes |
| LVIDs (mm) | 2.8 ± 0.4 | 2.5 ± 0.2 | 3.2 ± 0.3 | 2.1 ± 0.2 | 3.8 ± 0.2 | 3.2 ± 0.2 | 3.9 ± 0.1 | 3.5 ± 0.1 | ME-sex |
| S' (cm/sec; septum) | 3.4 ± 0.1 | 3.5 ± 0.1 | 3.7 ± 0.4 | 3.2 ± 0.1 | 3.5 ± 0.2 | 3.3 ± 0.2 | 3.4 ± 0.1 | 3.6 ± 0.2 | |
| DIASTOLIC FUNCTION | | | | | | | | | |
| LVAWd (mm) | 1.6 ± 0.2 | 1.9 ± 0.2 | 1.9 ± 0.1 | 2.1 ± 0.2 | 1.8 ± 0.1 | 2.0 ± 0.1 | 1.7 ± 0.1 | 2.1 ± 0.1 | |
| LVPWd (mm) | 1.3 ± 0.1 | 1.5 ± 0.2 | 1.3 ± 0.1 | 2.0 ± 0.2 | 1.4 ± 0.1 | 1.9 ± 0.1 | 1.5 ± 0.1 | 2.0 ± 0.1 | ME-sex, diabetes |
| LVIDd (mm) | 6.3 ± 0.4 | 6.0 ± 0.3 | 6.7 ± 0.3 | 6.0 ± 0.3 | 6.9 ± 0.2 | 6.7 ± 0.1 | 7.7 ± 0.2 | 7.1 ± 0.1 | ME-sex, diabetes (p=0.055) |
| IVRT (msec) | 18 ± 1 | 18 ± 1 | 16 ± 1 | 20 ± 1 | 17 ± 1 | 17 ± 1 | 22 ± 1 | 27 ± 1 | INT |
| E (cm/sec) | 119 ± 9 | 125 ± 8 | 123 ± 6 | 115 ± 5 | 105 ± 4 | 119 ± 5 | 119 ± 3 | 123 ± 5 | |
| A (cm/sec) | 67 ± 3 | 73 ± 2 | 101 ± 8 | 92 ± 3 | 75 ± 4 | 91 ± 8 | 91 ± 7 | 100 ± 6 | INT, ME-diabetes |
| E/A ratio | 1.81 ± 0.14 | 1.71 ± 0.11 | 1.24 ± 0.05 | 1.25 ± 0.05 | 1.41 ± 0.06 | 1.32 ± 0.06 | 1.35 ± 0.09 | 1.20 ± 0.05 | INT |
| E' (cm/sec; septum) | 5.5 ± 0.3 | 5.9 ± 0.5 | 5.5 ± 0.2 | 6.1 ± 0.2 | 4.9 ± 0.3 | 6.3 ± 0.3 | 5.0 ± 0.3 | 5.4 ± 0.2 | |
| A' (cm/sec; septum) | 2.9 ± 0.1 | 4.1 ± 0.4 | 4.0 ± 0.3 | 3.7 ± 0.3 | 3.3 ± 0.3 | 4.5 ± 0.2 | 4.0 ± 0.2 | 4.3 ± 0.3 | |
| E'/A' ratio | 1.9 ± 0.1 | 1.5 ± 0.1 | 1.4 ± 0.1 | 1.7 ± 0.2 | 1.5 ± 0.1 | 1.4 ± 0.1 | 1.2 ± 0.1 | 1.3 ± 0.1 | ME-sex, diabetes |
| Relative wall thickness | 0.42 ± 0.07 | 0.50 ± 0.05 | 0.40 ± 0.02 | 0.67 ± 0.09 | 0.42 ± 0.03 | 0.55 ± 0.02 | 0.40 ± 0.01 | 0.57 ± 0.03 | ME-diabetes |

Values are means \pm SEM. HR, heart rate; FS , fractional shortening; LV SV, left ventricular stroke volume; LVAWs, left ventricular systolic anterior wall thickness; LVPWs, left ventricular systolic posterior wall thickness; LVIDs, left ventricular internal systolic diameter; S', peak mitral annulus velocity during systole; LVAWd, left ventricular diastolic anterior wall thickness; LVPWd, left ventricular diastolic posterior wall thickness; LVIDd, left ventricular internal diastolic diameter; IVRT, isovolumic relaxation time; E, peak mitral flow velocity during early diastole; A, peak mitral flow velocity during atrial systole; E', early diastolic peak mitral annulus velocity; A', peak mitral annulus velocity during atrial systole. Stats: INT – Sex*DM interaction; ME – Main Effect of Sex or DM



Supplemental Fig. S1. Characterization of the metabolic phenotype in 3-month old ZL-F and ZDF-F rats.

Six-hour fasting blood collection at 3-months of age was performed to analyze (A) plasma glucose, (B) serum insulin, (D) triglycerides, (E) cholesterol, (F) high-density lipoprotein (HDL), (G) low-density lipoprotein (LDL) and (H) alanine aminotransferase (ALT). (C) HOMA-IR was calculated at the indicated ages using corresponding fasting plasma glucose and insulin values. (I) Body weight was measured at 3-months of age and (J and K) body composition was determined using the EchoMRI 4in1/1100, a QMR system that measures lean mass, fat mass, total water, and free water, in which rats were placed in an adjustable plastic cylinder to restrict movement. The cylinder (2.75 inches in diameter) has openings on either end to allow the animals to breathe freely. The cylinder was inserted into the EchoMRI for a reading that lasted for 85 seconds. Number of animals per group ranged from 8-11. Values are means \pm SEM. $n=5$ for ZL-F and ZDF-F. * $p<0.05$ vs. ZL-F by unpaired *t*-test.

Supplemental Table S2. Echocardiography parameters of 3-month old ZL and ZDF female rats.

| Parameter | ZL-F | ZDF-F | p-value |
|---|----------------------|-------------------|---------|
| SAX, M-Mode | | | |
| Systolic function | | | |
| Heart Rate (bpm) | 365 ± 9 | 364 ± 10 | 0.9472 |
| Stroke Volume (μL) | 192 ± 9 | 197 ± 6 | 0.6681 |
| EF% | 81.05 ± 1.46 | 84.15 ± 1.60 | 0.1253 |
| FS% | 51.21 ± 1.52 | 55.39 ± 1.88 | 0.0982 |
| Diastolic function | | | |
| LVAWd (mm) | 1.71 ± 0.08 | 1.94 ± 0.06 | 0.04 |
| LVIDd (mm) | 6.67 ± 0.15 | 6.72 ± 0.11 | 0.81 |
| IVRT (ms) | 16.99 ± 1.07 (10) | 19.87 ± 1.30 (10) | 0.10 |
| E (mm/s) | 1003.18 ± 46.41 (11) | 875.42 ± 28.85 | 0.03 |
| E' (mm/s) | 67.72 ± 3.50 (11) | 48.22 ± 2.33 | <0.01 |
| Myocardial strain | | | |
| Endocardial SAX | | | |
| Radial strain | 24.28 ± 2.66 (11) | 15.91 ± 2.15 (11) | 0.02 |
| Radial strain rate, 1/s | 5.15 ± 0.35 (11) | 3.75 ± 0.35 (11) | 0.01 |
| Circumferential strain | -22.71 ± 1.71 | -25.08 ± 2.56 | 0.45 |
| Circumferential strain rate, 1/s | -5.00 ± 0.40 | -7.16 ± 0.78 | 0.06 |
| Endocardial PLAX | | | |
| Radial strain | 24.15 ± 1.58 (10) | 9.19 ± 1.88 (8) | <0.01 |
| Radial strain rate, 1/s | 4.84 ± 0.36 (11) | 3.50 ± 0.32 (11) | 0.01 |
| Longitudinal strain | -17.49 ± 2.09 | -15.42 ± 2.02 | 0.48 |
| Longitudinal strain rate, 1/s | -5.39 ± 0.61 | -4.51 ± 0.38 | 0.23 |
| Epicardial SAX | | | |
| Circumferential strain | -8.83 ± 0.74 | -7.14 ± 0.68 (11) | 0.11 |
| Circumferential strain rate, 1/s | -2.03 ± 0.17 | -1.88 ± 0.13 | 0.50 |
| Epicardial PLAX | | | |
| Longitudinal strain | -9.58 ± 0.78 (9) | -7.04 ± 0.62 (9) | 0.02 |
| Longitudinal strain rate, 1/s | -2.07 ± 0.27 | -2.07 ± 0.17 | 0.99 |
| <i>n=12 unless otherwise indicated in parentheses</i> | | | |

EF, Ejection Fraction; FS, Fractional Shortening, LVAWd, left ventricular diastolic anterior wall thickness; LVIDd, left ventricular internal diastolic diameter; IVRT, isovolumic relaxation time; E, peak mitral flow velocity in early diastole; E', early diastolic peak mitral annulus velocity; SAX: Short Axis view; PLAX: Parasternal long-axis view. *p*-values are listed and were determined by unpaired *t*-test.

Supplemental Table S3 Chemokine/cytokine fold change values as determined by Ray Biotech Quantibody-Rat Cytokine Array Q67. ZL-F = Zucker lean-female, ZL-M = Zucker lean-male, ZDF-F = Zucker diabetic fatty-female, ZDF-M = Zucker diabetic fatty-male. **Bolded** values indicate significance between respective groups compared ($p < 0.05$) via pairwise Student T-test.

| Chemokine/cytokine | Fold-change ZL-F/ZL-M | Fold-change ZDF-F/ZDF-M | Fold-change ZDF-F/ZL-F | Fold-change ZDF-M/ZL-M | Classification |
|--------------------|--------------------------|----------------------------|---------------------------|---------------------------|-------------------|
| 4-1BB | -1.67 | 2.55 | -1.03 | -4.39 | Receptor |
| Activin A | --- | 5.07 | --- | -21.26 | Receptor |
| Adiponectin | -1.44 | 2.02 | -1.06 | -3.07 | Adipokine |
| b-NGF | 2.15 | 1.52 | -1.38 | 1.02 | Growth Factor |
| B7-1 | 1.23 | 1.48 | -1.51 | -1.82 | Receptor |
| B7-2 | 5.96* | 4.22* | 1.21 | 1.70 | Receptor |
| CD48 | -1.29 | 5.47 | 1.66 | -4.26 | Receptor |
| CINC-1 | 2.16 | 2.35 | 1.35 | 1.23 | CXC Chemokine |
| CINC-2 | 3.31* | 2.55* | 1.29 | 1.67 | CXC Chemokine |
| CINC-3 | 4.97* | 3.97 | -1.80 | -1.43 | CXC Chemokine |
| CNTF | -1.47 | 1.22 | 1.11 | -1.61 | Cytokine |
| CTACK | -1.16 | 2.64 | 1.48 | -2.08 | CC Cytokine |
| Decorin | 1.15 | 1.03 | -1.29* | -1.16 | Ligand |
| Eotaxin | -1.49 | 1.53 | 1.24 | -1.84 | CC chemokine |
| EphA5 | 5.48 | 1.01 | -2.99 | 1.81 | Receptor |
| Erythropoietin | 2.72 | 1.78 | -1.34 | 1.14 | Cytokine |
| FGF-BP | 1.41 | 1.25 | -1.61 | -1.43 | Growth Factor |
| Flt-3L | -2.02 | 1.18 | -1.50 | -3.55 | Ligand |
| Fractalkine | 1.71 | 1.05 | -1.24 | 1.31 | Chemokine |
| Galectin-1 | 1.52 | 1.00 | -1.37 | 1.11 | Receptor |
| Galectin-3 | 2.04* | 1.48 | 1.17 | 1.61 | Receptor |
| Gas 1 | -2.85* | -1.03 | -1.09 | -3.01* | Tumor Suppressor |
| GFR alpha-1 | -1.07 | -1.20 | -1.18 | -1.05 | Receptor |
| GM-CSF | 1.00 | 1.46 | -1.13 | -1.64* | Cytokine |
| gp130 | 1.06 | 4.28 | 3.42 | -1.17 | Receptor |
| HGF | 1.14 | 2.77 | 1.10 | -2.21 | Growth Factor |
| ICAM-1 | -1.25 | 1.16 | 1.03 | -1.41 | Receptor |
| IFNg | 1.09 | 1.63 | -1.08 | -1.61* | Cytokine |
| IL-1 R6 | 4.46 | -1.41 | -2.00 | 3.14 | Receptor |
| IL-1 ra | 1.49 | 1.69 | 1.34 | 1.18 | Cytokine |
| IL-10 | 1.07 | 2.09* | 1.11 | -1.75* | Cytokine |
| IL-13 | 4.91 | 2.16 | -1.08 | 2.11 | Cytokine |
| IL-17F | -1.06 | -1.40 | -3.95 | -3.00 | Cytokine |
| IL-1a | 5.31 | 2.50 | -1.19 | 1.78 | Cytokine |
| IL-1b | 1.13 | 1.61 | -1.27 | -1.82* | Cytokine |
| IL-2 | 1.32 | 2.28* | 1.07 | -1.61* | Cytokine |
| IL-2 Ra | 1.32 | 1.65 | -1.50 | -1.87 | Receptor |
| IL-22 | -172.65 | --- | --- | --- | Cytokine |
| IL-3 | 5.05 | -1.83 | -4.72 | 1.96 | Cytokine |
| IL-4 | 1.11 | 1.57 | -1.28 | -1.82* | Cytokine |
| IL-6 | 1.70 | -1.15 | -2.50* | -1.28 | Cytokine |
| IL-7 | 0.97 | -1.09 | -1.35 | -1.29 | Cytokine |
| JAM-A | 1.23 | -1.01 | -1.19 | 1.05 | Adhesion Molecule |
| L-Selectin | 3.98* | 2.78 | -1.07 | 1.34 | Adhesion Molecule |
| LIX | 3.03* | 1.48 | -1.45 | 1.42 | CXC Chemokine |
| MCP-1 | 1.05 | 1.52 | -1.15 | -1.67* | CC Chemokine |
| MIP-1a | --- | --- | --- | --- | CC Chemokine |
| Neuropilin-1 | -1.27* | -1.26* | -1.68* | -1.69* | Receptor |
| Neuropilin-2 | -1.26 | -1.05 | -1.68 | -2.01 | Receptor |

| | | | | | |
|-------------|--------------|--------------|-------|---------------|-------------------|
| Nope | 1.22 | -1.32 | -1.54 | 1.04 | Adhesion Molecule |
| Notch-1 | 1.11 | 1.03 | -1.50 | -1.40 | Receptor |
| Notch-2 | -1.43 | -1.48 | -2.33 | -2.26 | Receptor |
| P-Cadherin | -1.26 | 4.93 | 6.77 | 1.09 | Adhesion Molecule |
| PDGF-AA | 3.01 | 1.07 | -2.56 | 1.09 | Growth Factor |
| Prolactin | 1.74 | 1.93 | -1.46 | -1.62 | Growth Factor |
| Prolactin R | 1.52 | 2.48* | 1.08 | -1.51 | Receptor |
| RAGE | -1.82 | 8.34 | 1.12 | -13.59 | Receptor |
| RANTES | 1.11 | 1.95 | -1.93 | -3.39 | CC Chemokine |
| SCF | 1.13 | 1.91 | -1.54 | -2.60 | Growth Factor |
| TCK-1 | 1.16 | -1.02 | -1.24 | -1.05 | CXC Chemokine |
| TIM-1 | 1.24 | 1.31 | -1.03 | -1.08 | Receptor |
| TIMP-1 | -1.35 | 2.79* | 1.61 | -2.35* | MMP Inhibitor |
| TIMP-2 | --- | --- | --- | --- | MMP Inhibitor |
| TNFa | 1.11 | 1.70 | -1.24 | -1.91 | Growth Factor |
| TREM-1 | 2.03 | 1.99 | -1.10 | -1.08 | Receptor |
| TWEAK R | -1.09 | 1.06 | -1.15 | -1.33 | Receptor |
| VEGF | 4.68* | 1.63 | -2.23 | 1.28 | Growth Factor |